Ligand Pharmaceuticals (LGND) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $64 million, a 34% increase year-over-year.

Royalty Revenue: $48 million, up 32%, driven by strong performances from Filspari, Ohtuvayre, and Zelsuvmi.

Adjusted EPS: Increased 48% to $2.37, reflecting operational scalability.

Balance Sheet: Post-acquisition of XOMA, Ligand has approximately $700 million of deployable capital and expects operating cash flow of over $200 million in 2026, growing to $300 million in 2027.

2Strategic Updates and Business Highlights

XOMA Acquisition: Closed shortly after the quarter-end, adding over 120 assets to Ligand's portfolio, including significant commercial royalty streams and nearly doubling the late-stage clinical pipeline.

Financing Strategy: Successfully completed a $700 million zero-coupon convertible offering, enhancing financial flexibility and capacity for future investments.

Royalty Aggregation Strategy: Ligand continues to focus on building a diversified royalty portfolio, benefiting from a strong market for royalty investing.

Pipeline Expansion: The company is entering a catalyst-rich period with multiple FDA approvals and pivotal trial readouts expected over the next 18 months.

3Forward Guidance and Outlook

Adjusted EPS Guidance: Increased to a range of $9 to $9.50 for 2026, reflecting the contribution from the XOMA acquisition and share repurchases.

Royalty Revenue Guidance: Maintained at $225 million to $250 million for 2026.

Total Revenue Guidance: Expected between $270 million and $310 million, with Captisol revenue projected at $35 million to $40 million.

4Bad News, Challenges, or Points of Concern

Kyprolis Sales Decline: Amgen reported a 17% year-over-year decrease in Kyprolis sales, which could impact royalty revenue.

Regulatory Risks: The FDA's recommendation for a Phase III trial for Mirum's PSC product may delay approval timelines, although the company remains optimistic about eventual success.

Integration Risks: While the XOMA acquisition is expected to be accretive, integrating such a large portfolio poses operational challenges.

5Notable Q&A Insights

XOMA Portfolio Surprises: Management noted positive developments in previously undervalued assets within the XOMA portfolio, indicating potential for future growth.

Focus on Early-Stage Assets: Ligand is exploring investments in early-stage assets from the XOMA acquisition, which may yield promising opportunities despite being outside their traditional focus.

Competitive Landscape: Ligand's CEO emphasized the low competition in the royalty financing space, positioning the company favorably for future growth.

Tax Benefits: The acquisition of XOMA brings over $110 million in tax credits and net operating losses, which will enhance cash generation over the next few years. Overall, Ligand Pharmaceuticals reported strong financial performance in Q2 2026, driven by strategic acquisitions and a robust royalty revenue model, while also navigating regulatory challenges and integration complexities.